Market volatility and selective investor appetite have tempered the IPO window in late 2026, with 254 U.S. deals completed year-to-date but concentrated in smaller biotechs and SPACs rather than large technology or fintech offerings. Recent withdrawals, including Firmus at a targeted $30 billion valuation, reflect caution over equity pricing and economic uncertainty, while upcoming candidates such as Iambic Therapeutics and City Therapeutics illustrate modest biotech activity. High-profile names including Anthropic, OpenAI, and Stripe face extended timelines amid demands for premium valuations, with marketing or filings unlikely to close before year-end absent a sharp improvement in risk appetite or benchmark yields.